Showing results (21-30 of 164) with videos related to
Sort By:
Pageof 17
Frontiers in Immunology|July 12, 2021
Targeting Bruton's Tyrosine Kinase in CLLInhye E Ahn, Jennifer R BrownHematology. American Society of Hematology. Education Program|December 4, 2020
Future of CAR T cells in multiple myelomaKitsada Wudhikarn, Sham Mailankody, Eric L SmithNature Reviews. Clinical Oncology|March 15, 2017
The high price of anticancer drugs: origins, implications, barriers, solutionsVinay Prasad, Kevin De Jesús, Sham MailankodyHematology/Oncology Clinics of North America|June 17, 2023
The Role of Chimeric Antigen Receptor T-Cell Therapy in the Era of Bispecific AntibodiesKarthik Nath, Sham Mailankody, Saad Z UsmaniClinical Lymphoma, Myeloma & Leukemia|December 3, 2013
Successful long-term treatment of Philadelphia chromosome-negative myeloproliferative neoplasms with combination of hydroxyurea and anagrelideInhye E Ahn, Ethan Natelson, Lawrence RiceClinical Advances in Hematology & Oncology : H&O|February 6, 2015
Smoldering multiple myeloma: pathophysiologic insights, novel diagnostics, clinical risk models, and treatment strategiesDickran Kazandjian, Sham Mailankody, Neha Korde, et al.CMAJ Open|January 19, 2018
Most medical practices are not parachutes: a citation analysis of practices felt by biomedical authors to be analogous to parachutesMichael J Hayes, Victoria Kaestner, Sham Mailankody, et al.Frontiers in Oncology|August 23, 2024
Chimeric antigen receptor T-cells: a review on current status and future directions for relapsed/refractory multiple myelomaIssam S Hamadeh, Reed Friend, Sham Mailankody, et al.Clinical Pharmacology and Therapeutics|September 26, 2023
CAR T-Cell Therapy for Multiple Myeloma: A Clinical Practice-Oriented ReviewNorah Layla Sadek, Bruno Almeida Costa, Karthik Nath, et al.JAMA Network Open|February 24, 2021
Assessment of Outcomes Associated With the Use of Newly Approved Oncology Drugs in Medicare BeneficiariesAngela K Green, Michael Curry, Niti Trivedi, et al.Pageof 17